BofA lowered the firm’s price target on Cytokinetics (CYTK) to $70 from $75 and keeps a Neutral rating on the shares after the company presented the full SEQUOIA dataset for aficamten in obstructive hypertrophic cardiomyopathy, or oHCM. Putting ” cross-trial caveats aside,” the firm suspects some surprise the values are in-line to below Bristol’s (BMY) Camzyos’ after outperformance of the former’s pVO2 top-line, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
- Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
- Cytokinetics price target lowered to $106 from $107 at Oppenheimer
- Cytokinetics price target lowered to $106 from $110 at JMP Securities
- Cytokinetics Reports First Quarter 2024 Financial Results